Never stack high doses with blood thinners, and stop ginkgo 1 to 2 weeks before any surgery
Some people tolerate tirzepatide with no sulfur burps but cannot handle semaglutide, and vice versa
Recently Novo Nordisk announced the initiation of REDEFINE 4, a phase 3 trial comparing CagriSema 2.4 mg with Lillys Zepbound 15 mg evaluating weight loss after 72 weeks in 800 obese patients non-diabetic and is expected to be completed by October 2025 (NCT06131437)
During this period, blood glucose monitoring should be intensified to guide any necessary adjustments to alternative diabetes therapies
Operating the device relies on a straightforward, sequential technique: Preparation & Injection: Attach a new single needle for each dose, select and clean the site, and insert the needle subcutaneously
This creates a translational gap